Original language | English |
---|---|
Pages (from-to) | 338-340 |
Number of pages | 3 |
Journal | Pediatric pulmonology |
Volume | 56 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2021 |
Keywords
- misperception
- severe asthma
- short-acting beta agonist
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Pediatric pulmonology, Vol. 56, No. 2, 02.2021, p. 338-340.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Discordant use of short-acting β2 agonists in children and adults with severe, uncontrolled asthma from the U-BIOPRED cohort
AU - The U-Biopred Study Group
AU - Gorlanova, Olga
AU - Tischhauser, Eveline
AU - Adcock, Ian M.
AU - Chung, Kian Fan
AU - Fleming, Louise
AU - Meier, Delphine
AU - Sterk, Peter J.
AU - Roberts, Graham
AU - Roberts, Amanda
AU - Singer, Florian
AU - Sousa, Ana R.
AU - Uddin, Mohib
AU - Frey, Urs
N1 - Funding Information: U‐BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007‐2013) and EFPIA companies' in‐kind contribution ( https://www.imi.europa.eu ). The authors would like to acknowledge help from the IMI‐funded eTRIKS project (EU Grant Code no. 115446). This study is registered on https://ClinicalTrials.gov (identifier: NCT01982162). Funding Information: U-BIOPRED is supported through an Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115010, resources of which are composed of a financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in-kind contribution (https://www.imi.europa.eu). The authors would like to acknowledge help from the IMI-funded eTRIKS project (EU Grant Code no. 115446). This study is registered on https://ClinicalTrials.gov (identifier: NCT01982162). Funding Information: Mohib Uddin is an employee of AstraZeneca and holds shares in the company. Florian Singer reports personal fees from Vertex, personal fees from Novartis, grants from Swiss Society of Cystic Fibrosis (CFCH), grants from LUNGENLIGA BERN, outside the submitted work. Peter J. Sterk reports grants from public‐private funding to his institute by the Innovative Medicines Initiative covered by the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), during the conduct of the study. Ian M. received grants from EU‐IMI, during the conduct of the study. The other authors declare that there are no conflict of interests.
PY - 2021/2
Y1 - 2021/2
KW - misperception
KW - severe asthma
KW - short-acting beta agonist
UR - http://www.scopus.com/inward/record.url?scp=85096666786&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/ppul.25171
DO - https://doi.org/10.1002/ppul.25171
M3 - Article
C2 - 33231935
SN - 8755-6863
VL - 56
SP - 338
EP - 340
JO - Pediatric pulmonology
JF - Pediatric pulmonology
IS - 2
ER -